The site, located in Hillerød, Denmark, is now the fourth pharmaceutical manufacturing facility of Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm after a $890m (€794.3m) investment.
Now owned by the contract development and manufacturing organization (CDMO), the site will change its name to Fujifilm Diosynth Biotechnologies Denmark ApS.
The facility is equipped with six 15,000L bioreactors for the manufacture of cell culture-derived biologics for clinical and commercial use. The site also houses an assembly, labeling and packaging facility, quality control laboratories and warehouses.
Products manufactured at the site under Biogen will continue to be supplied by the facility under the ownership of Fujifilm.
A spokesperson for Fujifilm told us that the company is working to expand its global business lines to become a “total healthcare company” and to do is working to enhance the growth of its healthcare business by investing in its bio-CDMO business.
Investments in this business include expansions of the manufacturing sites operated by Fujifilm subsidiaries. The spokesperson added that the company views the Hillerød facility as a key asset in this investment.
Other Fujifilm Diosynth Biotechnologies already has production facilities for multi-product production including single-use 2,000L mammalian cell culturing tanks.
